ArticleERJ open research2025
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Introduction: Methods: This was a US retrospective cohort study using the TriNetX platform between 2008 and 2019. Adult patients with (wPsA) or without (w/oPsA) PsA airway infection were included. Date of first exacerbation corresponded to the index date, and patients were followed for up to 5 years post index. Risk ratios (RR) for hospitalisation, subsequent exacerbation, mortality and incidence of pre-specified CV events were estimated. Propensity score matching (PSM) was used to balance baseline characteristics. Results: After PSM, patients wPsA infection were at a greater risk of hospitalisation (RR: 1.40; 95% CI: 1.19-1.64), subsequent exacerbation (RR: 1.70; 95% CI: 1.53-1.90) and mortality (RR: 1.37; 95% CI: 1.20-1.56) than patients w/oPsA. PsA infection was associated with a higher risk of dysrhythmias (RR: 1.32; 95% CI: 1.13-1.54), inflammatory heart disease (RR: 2.09; 95% CI: 1.29-3.37), other cardiac disorders (RR: 1.40; 95% CI: 1.14-1.72), thrombotic disorders (RR: 1.31; 95% CI: 1.01-1.68), major adverse cardiovascular events (RR: 1.35; 95% CI: 1.19-1.52) and any CV outcome (RR: 1.42; 95% CI: 1.24-1.62). Conclusion: PsA infection in patients with BE is associated with an increased risk of CV events following a baseline exacerbation. These data highlight the multisystemic nature of BE and the need to raise awareness of the potential increased risk of CV events in patients with BE experiencing exacerbations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.